Double Stranded Oligonucleotide Compounds Comprising Positional Modifications
AssigneeQuark Pharmaceuticals, Inc.
InventorsSharon Avkin-Nachum, Elena Feinstein, Leonid Beigelman
Life of this patent
Estimating the term…
Abstract
Disclosed herein are double stranded RNA molecules which have been modified to exhibit one of the following, increased activity, enhanced nuclease stability, reduced off target activity and or reduced immunogenicity, to pharmaceutical compositions comprising such compounds and to methods of use. Further disclosed is a method for the synthesis of threose nucleic acid phosphoramidites and methods of use thereof.
Claims33
A double stranded nucleic acid molecule having structure A1 set forth below:
- (A1) 5′ (N)x-Z 3′ (antisense strand)
- 3′ Z′-(N′)y-z″ 5′ (sense strand)
- wherein said double stranded nucleic acid molecule is an siRNA, siNA, or miRNA, and wherein each of N and N′ is a ribonucleotide that may be unmodified or modified, or an unconventional moiety;
- wherein each of (N)x and (N′)y is an oligonucleotide in which each consecutive N or N′ is joined to the next N or N′ by a covalent bond;
- wherein each of Z and Z′ is independently present or absent, but if present independently includes 1-5 consecutive nucleotides or non-nucleotide moieties or a combination thereof covalently attached at the 3′ terminus of the strand in which it is present;
- wherein z″ may be present or absent, but if present is a capping moiety covalently attached at the 5′ terminus of (N′)y;
- wherein each of x and y is independently an integer between 18 and 25;
- wherein the sequence of (N′)y has complementarity to the sequence of (N)x, and (N)x comprises an antisense sequence complementary to a consecutive sequence in a target RNA;
- and
- wherein the molecule comprises the following modification b and at least one of the following modifications a and c:
- a. a 2′5′ nucleotide or a mirror nucleotide is present in (N)x in at least one of positions 5, 6, 7, 8, or 9 from the 5′ terminus;
- b. a threose nucleic acid moiety is present in the sense strand at positions 14 and 16-19, positions 13-14 and 16-19, or positions 12-14 and 16-19, and a 2′5′ nucleotide is present in the same sense strand;
- and
- c. from 1 to 10 2′5′ nucleotides are present in (N′)y at the 3′ terminal or penultimate positions,
- wherein the threose nucleic acid is an L-alpha-threofuranosyl nucleotide.
-9. (canceled)
11-12. (canceled)
17-20. (canceled)
22-23. (canceled)
(canceled)
(canceled)
40-71. (canceled)
Dependencies are inferred from the claim text.